Medtide Inc. (HKG:3880)

Market Cap	2.82B -39.9%
Revenue (ttm)	635.93M +10.5%
Net Income	195.16M +52.8%
EPS	1.37 +34.6%
Shares Out	141.80M
PE Ratio	14.49
Forward PE	10.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,400
Open	19.97
Previous Close	19.92
Day's Range	18.13 - 19.98
52-Week Range	18.13 - 34.30
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 596
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3880

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error